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a  b  s  t  r  a  c  t
Aim:  We  sought  to evaluate  the  effect  of  radiation  therapy  on  post-prostatectomy  urinary  quality  of  life
in  prostate  cancer  patients.
Background:  In  some  men  with  non-metastatic  prostate  cancer,  radiation  therapy  is  indicated  fol-
lowing  prostatectomy.  The  radiation  toxicity  and  quality  of life  considerations  are unique in the
post-prostatectomy  setting.
Materials  and  methods:  A  total  of  106  patients  receiving  post-prostatectomy  radiation  therapy  completed
the  Expanded  Prostate  Cancer  Index  Composite  questionnaire  before  radiation  and  at  2-year  follow-up.
The  primary  outcomes  of this  study  were  the  urinary  domain  summary  score  and subscale  scores.  Planned
analysis  was  performed  based  on time  interval  from  prostatectomy  to radiation  therapy.
Results:  Among  the  106  patients  analyzed,  the  mean  urinary  domain  summary  score  worsened  at 2-
year  follow-up  after  radiation  therapy,  lowering  from  77.23–72.51  (p = 0.0085).  Similar  worsening  was
observed  in  the  subscales  of  function  (p = 0.003), bother  (p  =  0.0397),  and incontinence  (p  =  0.0003).  Uri-
nary  incontinence  showed  the  greatest  observable  change  among  subscales.  While  the  summary  score
worsened  (p  =  0.0031)  among  patients  receiving  radiation  therapy  more  than  1  year  after  prostatectomy,
it  did  not  show  statistically  significant  change  in those  treated  1 year  or  less  after  prostatectomy.
Conclusion:  Our  results  demonstrate  that post-prostatectomy  radiation  therapy  is  associated  with  modest
declines in  reportable  urinary  quality  of life.  Patients  receiving  radiation  therapy  more  than  1  year  after
prostatectomy  showed  greater  worsening  of  urinary  quality  of  life,  which  indicates  that  there  may  be no
functional  advantage  to delaying  radiation  therapy  beyond  the initial  postoperative  period.
© 2020  Greater  Poland  Cancer  Centre.  Published  by Elsevier  B.V. All  rights  reserved.. Introduction
Radical prostatectomy (RP) is an effective treatment for patients
ith non-metastatic prostate cancer (PrCa). Adjuvant externaleam radiation therapy (EBRT) is recommended to improve bio-
hemical and/or local control after RP, particularly in patients
hose radical prostatectomy specimens display high-risk patho-
Abbreviations: EBRT, external beam radiation treatment; EPIC, Expanded
rostate Cancer Index Composite; IPSS, International Prostate Symptom Score; MID,
inimally important differences; QOL, quality of life; RT, radiation therapy.
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biochemical, local, and/or distant control in patients who do not
undergo adjuvant EBRT and then have biochemical or clinical recur-
rence of PrCa3,4 months to years later. The decision to undergo EBRT
or pursue surveillance in the adjuvant setting is not straightforward
and requires careful consideration of the risks and benefits of both
options. Patient quality of life (QOL) is one of the crucial factors that
impacts this decision. Quality of life data after adjuvant EBRT are not
robust,5–8 unlike in the definitive EBRT setting where these are well
defined and include late toxicities such as urinary frequency, incon-
tinence, irritation, obstruction, or hematuria.9–14 Despite some data
pointing to an improved QOL after adjuvant EBRT,8 many clinicians
choose to defer EBRT to a later time due to concerns over QOL.
The International Prostate Symptom Score (IPSS), developed for
use in benign prostatic hypertrophy, is a useful tool to monitor
general urinary symptoms and has been validated for clinical use.
erved.
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Table  1
Patient characteristics.
Characteristic Mean Median Range
Age, y 64 65 41−81
Interval between RP and RT, mo 31  16 1−224


















































Radiation dose to prostate bed, Gy 69.94 70.00 68.00−76.60
bbreviations: RP, radical prostatectomy; RT, radiation therapy.
Among the various existing tools to measure QOL after PrCa
reatment, the Expanded Prostate Cancer Index Composite (EPIC)
uestionnaire is the one that is widely used and validated for
valuating toxicity across various methods of treating PrCa.15 The
urpose of this study is to evaluate whether, and to what degree,
BRT after RP impacts urinary QOL. To achieve this, we retrospec-
ively analyzed QOL data in the urinary function domain as reported
n the EPIC questionnaire. This information will aid patients and
linicians in making an informed decision about EBRT vs. surveil-
ance after RP.
. Materials and methods
Institutional review board approval was obtained prior to con-
ucting a retrospective patient review and the study was conducted
n accordance with the ethical standards of the committee on
uman experimentation. All patients who received post-RP EBRT
nd completed EPIC questionnaires at baseline and 2-year follow-
p comprised the study cohort. Patients completed follow-up
uestionnaires either at a follow-up visit or by mail. Prior data
ndicates that urinary QOL measured at the 2-year interval is
onsistent with longer-term measures of function; therefore, 2-
ear follow-up is the selected time interval by the institutions
tudied for obtaining repeat questionnaires.9 With institutional
eview board approval, we retrospectively reviewed the question-
aires completed by patients between April 2010 and September
017.
The primary endpoint measured in this study was  the EPIC
rinary domain summary score, using questions 23-34.15 Addition-
lly, the EPIC urinary subscale scores of function (questions 23–27),
other (28–34), incontinence (23, 26–28), and irritative/obstructive
24, 25, 29–33) symptoms were separately measured. The summary
nd subscale scores were normalized by a Likert scale of 0−100,
ith higher scores representing better reportable QOL. Supplement
able 1 shows the questions used for the scoring of each subscale.
A secondary endpoint was the IPSS score. Although origi-
ally developed for the evaluation of symptoms related to benign
rostatic hypertrophy,16 it is a simple, supplementary tool for
valuating overall urinary function. The EPIC questionnaire allows
or the formal inclusion of the IPSS as a non-scored component,
ut we analyzed it separately. The IPSS is reported on a scale
rom 0−35. Lower scores represent better reportable urinary func-
ion.
Planned analysis was also performed based on the time inter-
al from RP to EBRT. The impression exists that RT retards healing
nd that earlier treatment may  have a greater detriment on ulti-
ate functional outcome. We  sought to account for and assess that
ifference. Analysis was planned for 2 main groups: patients receiv-
ng EBRT 1 year or less after RP (early-radiation group) and those
eceiving EBRT more than 1 year after RP (late-radiation group).
We  also report on patients meeting minimally important differ-
nces (MID), which are used for identifying clinically meaningful
hreshold changes in EPIC scores. MIDs were previously devel-
ped by the PROST-QA Consortium using EPIC-2617 and are based
n standard deviations and secondary validation with satisfaction
uestionnaires. The PROST-QA Consortium determined a range ofy and Radiotherapy 25 (2020) 442–446 443
changes for clinical relevance for each subscale. Based on their
work, we  used the following MIDs to establish meaningful score
changes of 6–9 points for the incontinence and 5–7 points for the
irritative/obstructive subscales. The PROST-QA Consortium did not
report MIDs for the summary score, the function subscale, or the
bother subscale. However, based on results of the other subscales,
an MID  of 6–7 points is considered a reasonable endpoint.
Patients in this cohort were recommended for post-operative
radiotherapy due to persistently elevated PSA after prostatectomy,
adverse pathologic features or biochemical failure as defined by the
generally accepted definition of PSA ≥ 0.2 ng/mL.
2.1. Statistical analysis
Descriptive statistics were presented in the analysis. Mean, stan-
dard deviation, median, and range were reported for continuous
variables. The categorical variables were tabulated by correspond-
ing categories. The differences between EPIC domain and IPSS
scores as well as between the early and late-radiation groups from
baseline to first follow-up were assessed by Wilcoxon signed rank
test. P values of less than 0.05 were considered to indicate statistical
significance. All tests were two-sided. No adjustment on multi-
plicity was made. No imputation on missing data was  made. For
EPIC and IPSS scores, sensitivity analyses were implemented for the
patients whose EPIC urinary domain summary scores were greater
than the 25th percentile of all patients. All analyses were performed




106 patients completed QOL questionnaires at baseline and
at 2 year follow-up. The mean patient age was 64 years (range,
41–81 years). The mean time interval from baseline to comple-
tion of the follow-up questionnaire was  29 months (range, 17−52
months).
Of the 106 patients, 39 (37 %) and 67 (63 %) were in the early-
radiation and late-radiation group, respectively. The mean time
interval from RP to EBRT was  6 months and 46 months in the
early- and late-radiation groups, respectively (Table 1). All patients
received EBRT to a total dose of at least 68 Gy to the prostate bed.
3.2. QOL
A statistically significant decline in the mean IPSS score was
seen for the entire cohort from 8.21 at baseline to 9.71 at follow-up
(p = 0.0076) (Table 2). Similarly, a statistically significant decline in
the mean EPIC summary score was seen for the entire cohort from
77.23 at baseline to 72.51 at follow-up (p = 0.0085) (Tables 1 and 3).
The decline in the mean EPIC summary score was  magnified when
patients in the lowest (worst) quartile of reported baseline sum-
mary scores were excluded, with the mean declining from 86.28 at
baseline to 78.42 (p = 0.0005).
The mean score significantly declined in three of the four sub-
scales: function (p = 0.0030), bother (p = 0.0397), and incontinence
(p = 0.0003) (Table 3). The subscale with the greatest magnitude
change was  incontinence, which worsened by more than 10 points
from 66.49–56.14 (p = 0.0003).
In the early-radiation group, the mean EPIC summary score
declined from 76.63–74.76, but the change was not statistically
significant (p = 0.5888) (Supplement Table 2). In the late-radiation
group, the mean EPIC summary score also declined but with a
greater magnitude (77.58–71.19) and with a statistical significance
(p = 0.0031).
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Table  2
Effect of post-radical prostatectomy radiation on urinary function as measured by the International Prostate Symptom Score.
Patient group (No.) Mean Median Range P-value
All, 106 Base 8.21 6.0 0−32 0.0076
Post 9.71 8.0 0−35
Upper 75th percentilea,
77
Base 5.94 4.0 0−22 0.0042
Post 7.89 7.0 0−35
Early radiation groupb,
39
Base 9.34 7.5 0−32 0.4708
Post 8.08 7.0 1−26
Late-radiation groupc,
67
Base 7.56 5.5 0−30 < 0.0001
Post  10.66 10.0 0−35
Abbreviations: base, baseline measurement; post, post-radiation 2-year follow-up measurement.
a The upper 75th percentile is an evaluation that excludes the patients with the poorest function (lowest 25th percentile) based on the baseline EPIC urinary domain
summary score.
b The early radiation group is composed of patients receiving radiation therapy 1 year or less after prostatectomy.
c The late-radiation group is composed of patients receiving radiation therapy more than 1 year after prostatectomy.
Table 3
Effect of post-prostatectomy radiation on urinary function as measured by Expanded Prostate Cancer Index Composite (EPIC).
Patient Group, No. Mean Median Range p-value
Urinary Domain Summary Score
All patients, 106 Base 77.23 80.58 21.50−100 0.0085
Post  72.51 75.00 6.92−100
Upper 75th percentilea,
77
Base 86.28 86.83 67.42−100 0.0005
Post  78.42 82.67 6.92−100
Urinary Subscale Scores
Function Base 77.76 81.00 11.60−100 0.0030
Post  72.04 71.80 6.60−100
Bother Base 76.83 82.14 28.57−100 0.0397
Post  72.84 78.57 7.14−100
Incontinence Base 66.49 71.00 0.00−100 0.0003
Post 56.14 58.50 0.00−100
Irritative/obstructive Base 85.04 89.29 32.14−100 0.4498
Post  83.66 85.71 7.14−100
Abbreviations: base, baseline measurement; post, post-radiation 2-year follow-up measurement.
a The upper 75th percentile is an evaluation excluding the patients with the poorest function (lowest 25th percentile) based on the baseline EPIC urinary domain summary
score.
Table 4
For each EPIC urinary subscale, the differences between patients in the early and late-radiation groups at baseline (base) and follow-up (post).
Early radiation groupa Late-radiation groupb
Mean Median Range p-value Mean Median Range p-value
Summary Score
Base 76.63 79.17 21.5−100 0.5888 77.58 82.67 32.58−100 0.0031
Post 74.76 79.92 6.92−100 71.19 73.67 25.67−100
Subscale
Function
Base 75.73 78.40 11.6−100 0.7422 78.96 85.00 26.6−100 0.0001
Post 73.79 78.40 6.6−100 71.01 66.80 35.0−100
Bother
Base 77.20 79.17 28.57−100 0.7432 76.61 82.14 28.57−100 0.3663
Post 75.46 85.71 7.14−100 71.32 78.57 14.29−100
Incontinence
Base 64.37 66.75 8.25−100 0.4043 67.74 73.00 0−100 < 0.0001
Post  59.39 66.75 0−100 54.25 52.00 0−100
Irritative/Obstructive
Base 85.74 89.29 32.14−100 0.8619 84.63 87.50 42.86−100 0.3235










a The early radiation group is composed of patients receiving radiation therapy 1
b The late-radiation group is composed of patients receiving radiation therapy m
Patients in the early- and late-radiation groups reported
orsening QOL in each of the individual urinary subscales
Table 4). In the late-radiation group, the incontinence sub-
cale worsened from 67.74 to 54.25 (13.49 point change,
 < 0.0001). In the early-radiation group, the incontinence sub-
cale score also decreased from 64.37–59.39 (4.98 point change,
 = 0.4043).
Forty-nine percent of all patients had meaningful worsen-
ng of the incontinence subscale, based on MIDs (Fig. 1). Afterr less after prostatectomy.
an 1 year after prostatectomy.
excluding the 25% of patients with the lowest baseline incontinence
scores, the proportion of patients reporting meaningful worsen-
ing of incontinence is higher at 56% (Fig. 2). Any improvement in
the incontinence subscale score was seen in 25% of all patients.
In the early-radiation group, 44% experienced meaningful worsen-
ing of incontinence, compared with 52% of the late-radiation group
(Fig. 2). Improvement in the incontinence score was  seen in 36% of
the early-radiation group, compared with 18% of the late-radiation
group.
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Fig. 1. Proportion of patients reporting change in subscale score. Shown by subscale
score are the percentages of all reporting patients experiencing changes in scores
from before post-prostatectomy radiation through 2-year follow-up. Improvement
includes patients reporting any increase in score. Decline includes patients reporting
a  decline in score based on reported Minimally Important Differences specific to each
subscale (see Materials and Methods section).
Fig. 2. Proportion of patients reporting change in incontinence subscale score.
Shown are the percentages of patients in each group experiencing changes in incon-
tinence subscale score from before post-prostatectomy radiation through 2-year
follow-up. Groups displayed include all patients, those receiving radiation 1 year of
less  after prostatectomy (< or =1 year) or more than 1 year after prostatectomy (>
1  year). Improvement includes any patient reporting any increase in score. Decline
includes any patient reporting a decline in score of 6 or more based on reported










upper 75th percentile) is an evaluation that excludes the patients with the poor-
st function (lowest 25th percentile) based on the baseline EPIC urinary domain
ummary score.
. Discussion
It is not unexpected that long-term, perceivable functional
eclines occur after radiation. Ours is one of the first reports to
uantify those changes from patients’ perspective, specifically in
he post-RP setting. The EPIC and IPSS questionnaires provide
atient self-assessment of urinary function and QOL. Although
ollow-up beyond 2 years would be informative, prior data indi-y and Radiotherapy 25 (2020) 442–446 445
cates that urinary QOL measured at the 2-year interval is consistent
with longer-term measures of function.9 Thoughtful work has been
done to determine the degree of functional change that would be
meaningful to the patient.17 MIDs have helped establish thresh-
old changes in scores that represent clinically meaningful changes.
Across the subscales, a score in the 5- to 9-point range appears
to be a clinically meaningful change (see Methods section), with
some slight variation across the different subscales. The decline
in the EPIC urinary domain summary score we observed for the
entire cohort (77.23–72.51) barely approaches the lower end of that
threshold—a difference that can mostly be accounted for by changes
in the incontinence subscale. Specifically, a borderline decrement
existed in the function subscale, which is heavily influenced by uri-
nary control, but did not exist in the bother or irritative/obstruction
subscales.
Arguably, from the patient’s perspective, the biggest life-
altering change occurs in the incontinence subscale. Not surpris-
ingly, the baseline mean score (66.49) reflects a significant impact
from surgery. Other series9 that look at pre- and postoperative dif-
ferences find that the incontinence subscale score declines from
> 90 at baseline to approximately 50 at 2 months and 60–70 at 6
months, which is similar to our baseline levels. In our series, we
found that EBRT lowered the mean score from 66.49–56.14. This
change easily exceeds the MID  threshold (6–9 points) for signifi-
cance but, in perspective, is only a minor further decline from what
has occurred with RP.
It is surprising and, therefore, interesting that patients treated
in the first year after RP fared better with incontinence than those
treated later. This was  similar across the other subscale scores
where the late-radiation group consistently reported a greater
magnitude of change compared with the early-radiation group.
Conventional thinking has been that EBRT will have a greater detri-
ment on function the earlier it is delivered, ostensibly because of
impairment on healing. This scenario may  be true in the first 2
months after RP because prior studies have shown that most of
the improvement in continence occurs as previously noted.9 Our
inability to demonstrate a greater detriment to earlier versus later
treatment may  be that the median time to EBRT was 6 months in
our early-radiation group. It appears that a delay of just 2–3 months
after RP is an adequate interval to prevent healing impairment. The
fact that the early-radiation group fares better overall than the late-
radiation group may  be due to ongoing active healing that is able
to overcome any further detrimental effects on healing influenced
by EBRT. Another possibility is that any worsening of the incon-
tinence subscale in the early-radiation group was overshadowed
by the postsurgical improvement in continence that is known to
occur. We  were limited in this study in our ability to further sub-
divide patients based on time intervals from RP to EBRT (e.g., <
3 months, 3–6 months, and 6–12 months) while still maintaining
robust patient numbers in each group.
Our current practice is to recommend immediate post-operative
radiation in patients with a persistently elevated PSA or other
adverse pathologic features such as seminal vesicle invasion,
extraprostatic extension or positive surgical margins. In patients
with only minimal adverse features, such as an undetectable PSA
with a focal positive margin, we discuss the alternative of close PSA
surveillance. Given the findings presented here, we can more con-
fidently counsel these patients that deferring radiotherapy until a
PSA recurrence does not appear to significantly reduce the risks of
urinary toxicity from post-operative radiotherapy.5. Conclusions
We have documented through patient assessment that perma-
















16. Barry MJ,  Fowler FJ, O’Leary MP,  et al. The American Urological Association
symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557.
17. Skolarus TA, Dunn RL, Sanda MG,  et al. Minimally important difference
for the expanded prostate cancer index composite short form. Urology.
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he changes are modest in the EPIC urinary domain summary
core and across the specific subscales of function, bother, and irri-
ative/obstruction. The greatest changes are in the incontinence
ubscale. Although clearly meaningful, the changes are consid-
rably less in absolute magnitude compared with the changes
ccurring after RP. These findings should be beneficial to patients
nd clinicians as they consider the risks and benefits of post-RP
BRT.
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